#USA #Phoenix #MolecuLight #Bacterial Imaging #Burn Care

Advancing Burn Care with MolecuLight at ABA 2025

MolecuLight, a leader in the realm of point-of-care fluorescence imaging, is set to make significant waves at the upcoming American Burn Association (ABA) Annual Meeting, taking place from April 8 to 11 in Phoenix, Arizona. This event will gather some of the foremost experts in burn care, and MolecuLight’s techniques are poised to redefine standard practices in burn management through innovative bacterial detection methods.

Innovative Imaging Solutions

The focus of MolecuLight's presentation at the ABA meeting will be its state-of-the-art fluorescence imaging systems. These groundbreaking technologies allow medical professionals to visualize bacterial presence in wounds without invasive procedures. This immediate access to information is not just a technical feat, it fundamentally alters how providers approach patient care. With real-time imaging, clinicians can make expedited decisions, potentially enhancing recovery outcomes for burn victims.

MolecuLight will host live demonstrations showcasing its flagship products, the MolecuLight iX® and MolecuLight DX™ imaging devices. Attendees can visit Booth #626 to engage with esteemed professionals like Dr. Erik Hanson-Viana and learn firsthand how these imaging systems can influence clinical decision-making by offering precise bioburden assessments.

Clinical Insights Presented by Experts

The conference will also feature presentations from specialists in the field. One noteworthy session will include Dr. Erik Hanson-Viana, a distinguished plastic and reconstructive surgeon from Hospital Angeles in Mexico City. He will be presenting groundbreaking research titled “Fluorescence Imaging-Guided Sampling Provides More Accurate and Actionable Microbiology Compared to the Levine Technique.”

This pivotal presentation, taking place on Wednesday, April 9th at 11:45 AM, highlights how the integration of MolecuLight’s technology into sampling methods enhances the precision of burn reconstruction outcomes. The findings suggest that adopting fluorescence imaging not only ensures better graft timing but also improves the quality of site selection, thus pushing the boundaries of traditional burn care practices.

Furthermore, Dr. Carlos Daniel Torres García, a surgical resident at Hospital Angeles, will unveil his award-winning research titled “Bacterial Fluorescence Signals Are Associated with Dermal Regeneration Template Infections in Burn Patients.” This session is scheduled for April 9th at 12:30 PM, and aims to establish a critical correlation between the bacterial loads detected by MolecuLight and the effectiveness of cellular tissue products in burn recovery.

His research recently garnered recognition at the 55th Annual Mexican National Plastic Surgery Congress, claiming the 2nd place award for Best Scientific Protocol, underscoring the relevance and impact of his findings.

Transforming Burn Care

The implications of MolecuLight's technology extend far beyond mere identification of bacterial presence. As stated by Dr. Hanson-Viana, “The ability to visualize bacteria in real-time... has far-reaching implications for improving burn wound reconstruction.” Immediate, actionable information enhances clinical interventions, which ultimately fosters more successful surgical outcomes. MolecuLight’s evidence-backed approach to wound management—with over 100 peer-reviewed publications supporting its efficacy—positions it at the forefront of medical imaging technology.

As healthcare professionals gather at the ABA 2025 Annual Meeting to discuss advancements in burn treatment, the integration of MolecuLight’s revolutionary imaging technology could well determine the future landscape of burn care. With a commitment to innovation and patient-centered outcomes, MolecuLight aims to transform how wounds are assessed and treated, driving better futures for patients suffering from burn injuries.